Literature DB >> 26038531

Vascular Endothelial Growth Factor Therapy for the Kidney: Are We There Yet?

Alejandro R Chade1.   

Abstract

Entities:  

Keywords:  cystic kidney; lymphatics; renal injury; vascular endothelial growth factor; vessels

Mesh：

Substances：

Year:  2015        PMID： 26038531      PMCID： PMC4696589          DOI： 10.1681/ASN.2015050491

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  26 in total

1.  Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat.

Authors:  Christine Maric-Bilkan; Elizabeth R Flynn; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-26

2.  Role of renal microcirculation in experimental renovascular disease.

Authors:  Radu Iliescu; Solana R Fernandez; Silvia Kelsen; Christine Maric; Alejandro R Chade
Journal:  Nephrol Dial Transplant       Date:  2009-11-23       Impact factor: 5.992

3.  VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury.

Authors:  Ellen C Leonard; Jessica L Friedrich; David P Basile
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-17

4.  The balance of autocrine VEGF-A and VEGF-C determines podocyte survival.

Authors:  Janina Müller-Deile; Kirstin Worthmann; Moin Saleem; Irini Tossidou; Hermann Haller; Mario Schiffer
Journal:  Am J Physiol Renal Physiol       Date:  2009-10-14

5.  Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome.

Authors:  Marcin Barylski; Edward Kowalczyk; Maciej Banach; Julita Ciecwierz; Lucjan Pawlicki; Jan Kowalski
Journal:  Angiology       Date:  2008-11-17       Impact factor: 3.619

6.  Effects of angiotensin II receptor blockers on diabetic nephropathy.

Authors:  Rigas Kalaitzidis; George L Bakris
Journal:  J Hypertens Suppl       Date:  2009-07

7.  Renoprotective effects of hepatocyte growth factor in the stenotic kidney.

Authors:  Nicholas Stewart; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-26

8.  Blood pressure, blood flow, and oxygenation in the clipped kidney of chronic 2-kidney, 1-clip rats: effects of tempol and Angiotensin blockade.

Authors:  Fredrik Palm; Maristela Onozato; William J Welch; Christopher S Wilcox
Journal:  Hypertension       Date:  2010-01-04       Impact factor: 10.190

9.  Endothelial progenitor cells restore renal function in chronic experimental renovascular disease.

Authors:  Alejandro R Chade; Xiangyang Zhu; Ronit Lavi; James D Krier; Sorin Pislaru; Robert D Simari; Claudio Napoli; Amir Lerman; Lilach O Lerman
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

10.  VEGF-C promotes survival in podocytes.

Authors:  R R Foster; S C Satchell; J Seckley; M S Emmett; K Joory; C Y Xing; M A Saleem; P W Mathieson; D O Bates; S J Harper
Journal:  Am J Physiol Renal Physiol       Date:  2006-03-08
View more
  4 in total

1.  RON Receptor Tyrosine Kinase Regulates Epithelial Mesenchymal Transition and the Expression of Pro-Fibrotic Markers via Src/Smad Signaling in HK-2 and NRK49F Cells.

Authors:  Jung Sun Park; Hoon-In Choi; Dong-Hyun Kim; Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Soo Wan Kim
Journal:  Int J Mol Sci       Date:  2019-11-04       Impact factor: 5.923

Review 2.  Molecular Mechanisms of the Acute Kidney Injury to Chronic Kidney Disease Transition: An Updated View.

Authors:  Francesco Guzzi; Luigi Cirillo; Rosa Maria Roperto; Paola Romagnani; Elena Lazzeri
Journal:  Int J Mol Sci       Date:  2019-10-06       Impact factor: 5.923

3.  Adipose-derived mesenchymal stem cells from patients with atherosclerotic renovascular disease have increased DNA damage and reduced angiogenesis that can be modified by hypoxia.

Authors:  Ahmed Saad; Xiang-Yang Zhu; Sandra Herrmann; LaTonya Hickson; Hui Tang; Allan B Dietz; Andre J van Wijnen; Lilach Lerman; Stephen Textor
Journal:  Stem Cell Res Ther       Date:  2016-09-09       Impact factor: 6.832

4.  Polyprenol-Based Lipofecting Agents for In Vivo Delivery of Therapeutic DNA to Treat Hypertensive Rats.

Authors:  Olga Gawrys; Monika Rak; Iwona Baranowska; Sylwia Bobis-Wozowicz; Karolina Szaro; Zbigniew Madeja; Ewa Swiezewska; Marek Masnyk; Marek Chmielewski; Elzbieta Karnas; Elzbieta Kompanowska-Jezierska
Journal:  Biochem Genet       Date:  2020-08-06       Impact factor: 1.890
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.